ImageneBio to Present at Leerink Healthcare Conference Amid Phase 2b Trial
Event summary
- ImageneBio to participate in fireside chat on March 10, 2026 at Leerink Global Healthcare Conference.
- Webcast available for 90 days post-event on Imagene IR website.
- Company currently conducting Phase 2b trial of IMG-007 for moderate-to-severe atopic dermatitis.
- IMG-007 is a nondepleting anti-OX40 monoclonal antibody targeting immunological diseases.
The big picture
ImageneBio’s participation in the Leerink conference comes as it advances its lead candidate, IMG-007, through critical Phase 2b trials. The biotech sector is increasingly focused on differentiated therapeutics for autoimmune diseases, with competition intensifying around novel mechanisms like OX40 targeting. Imagene’s ability to articulate a clear clinical and commercial strategy will be key in differentiating itself from peers.
What we're watching
- Trial Momentum
- The pace at which ImageneBio advances its Phase 2b trial for IMG-007 will determine its competitive positioning in the autoimmune and inflammatory disease space.
- Investor Sentiment
- How management's presentation at Leerink impacts investor confidence amid a crowded biotech landscape.
- Regulatory Pathway
- Whether IMG-007’s differentiated profile accelerates regulatory approval timelines compared to competitors.
Related topics